Back لقاح نوفافاكس Arabic Vaccí de Novavax contra la COVID-19 Catalan Vakcína Novavax proti covidu-19 Czech Novavax COVID-19-Impfstoff German Εμβόλιο COVID-19 της Novavax Greek Vacuna de Novavax contra la COVID-19 Spanish NVX-CoV2373 French Vaksin Covid-19 Novavax ID Vaccino anti COVID-19 Novavax Italian Novavax COVID-19ワクチン Japanese

Novavax COVID-19 vaccine

"Covovax" redirects here and is not to be confused with COVAX or Covaxin.

Novavax COVID-19 vaccine
Vaccine description
TargetSARS-CoV-2
Vaccine typeSubunit
Clinical data
Trade namesCovovax,[1] Nuvaxovid[2][3][4]
Other names
  • NVX-CoV2373[5]
  • TAK-019[6]
  • SARS-CoV-2 rS[7][8]
  • COVID-19 Vaccine (recombinant protein)[9]
  • NVX-CoV2601[10]
AHFS/Drugs.comMonograph
License data
Pregnancy
category
Routes of
administration		Intramuscular
ATC code
Legal status
Legal status
Identifiers
CAS Number
DrugBank
UNII
KEGG
Part of a series on the
COVID-19 pandemic
Scientifically accurate atomic model of the external structure of SARS-CoV-2. Each "ball" is an atom.
Scientifically accurate atomic model of the external structure of SARS-CoV-2. Each "ball" is an atom.
Timeline
2019
2020
2021
2022
2023
Locations
By country and territory
By conveyance
International response
National responses
Medical response
Vaccines
Current vaccines
Variants
Variants of concern
Other variants
Economic impact and recession
By country
By sport
Impacts
Long COVID
Society
Politics
virus icon COVID-19 portal

The Novavax COVID-19 vaccine, sold under the brand names Nuvaxovid and Covovax,[1] among others, is a subunit COVID-19 vaccine developed by Novavax and the Coalition for Epidemic Preparedness Innovations.[32]

Updated versions of the vaccine have been developed to provide coverage against the Omicron variant, with different formulas for 2023–2024 (containing a recombinant spike protein from lineage XBB.1.5)[33] and 2024–2025 (containing recombinant spike protein from lineage JN.1).[30]

  1. ^ a b "WHO issues emergency use listing to Novavax-Serum Institute's COVID-19 vaccine". Reuters. 17 December 2021. Archived from the original on 17 December 2021. Retrieved 17 December 2021.
  2. ^ a b c "Nuvaxovid APMDS". Therapeutic Goods Administration (TGA). 20 January 2022. Archived from the original on 5 February 2022. Retrieved 5 February 2022.
  3. ^ a b "Regulatory approval of COVID-19 vaccine Nuvaxovid". Medicines and Healthcare products Regulatory Agency (MHRA). 3 February 2022. Archived from the original on 3 February 2022. Retrieved 3 February 2022.
  4. ^ a b Cite error: The named reference Nuvaxovid EPAR was invoked but never defined (see the help page).
  5. ^ "EMA starts rolling review of Novavax's COVID-19 vaccine (NVX-CoV2373)" (Press release). European Medicines Agency (EMA). 3 February 2021. Archived from the original on 2 July 2021. Retrieved 30 June 2021.
  6. ^ "Novavax and Takeda Finalize License Agreement for Novavax' COVID-19 Vaccine Candidate in Japan; Takeda Initiates Phase 1/2 Trial in Japan" (Press release). GlobeNewswire. 26 February 2021. Archived from the original on 2 June 2021. Retrieved 29 May 2021.
  7. ^ "EMEA-002941-PIP01-20". European Medicines Agency (EMA). 16 March 2021. Archived from the original on 21 June 2021. Retrieved 29 June 2021.
  8. ^ "SARS-CoV-2 rS (NVX-CoV-2373) vaccine for prevention of COVID-19". secondary. Aust Prescr. 45 (2): 62. April 2022. doi:10.18773/austprescr.2022.012. PMC 9081941. PMID 35592366. Archived from the original on 26 March 2022. Retrieved 14 May 2022.
  9. ^ "Updates to the Prescribing Medicines in Pregnancy database". Therapeutic Goods Administration (TGA). 21 December 2022. Archived from the original on 3 April 2022. Retrieved 2 January 2023.
  10. ^ "Novavax 2023-2024 COVID-19 Vaccine Now Authorized and Recommended for Use in the U.S. - Oct 3, 2023". Novavax (Press release). 3 October 2023. Archived from the original on 4 October 2023. Retrieved 4 October 2023.
  11. ^ a b "TGA eBS - Product and Consumer Medicine Information Licence". Archived from the original on 5 February 2022. Retrieved 5 February 2022.
  12. ^ a b "AusPAR: SARS-CoV-2 rS with Matrix-M adjuvant". Therapeutic Goods Administration (TGA). 21 January 2022. Archived from the original on 24 March 2022. Retrieved 23 March 2022.
  13. ^ "Updates to the Prescribing Medicines in Pregnancy database". Therapeutic Goods Administration (TGA). 12 May 2022. Archived from the original on 3 April 2022. Retrieved 13 May 2022.
  14. ^ "AusPAR: SARS-CoV-2 rS vaccine with Matrix-M1 adjuvant". Therapeutic Goods Administration (TGA). 27 June 2022. Archived from the original on 16 July 2022. Retrieved 17 July 2022.
  15. ^ "AusPAR: SARS-CoV-2 rS vaccine with Matrix-M1 adjuvant". Therapeutic Goods Administration (TGA). 24 June 2022. Archived from the original on 16 July 2022. Retrieved 17 July 2022.
  16. ^ "Novavax) (Biocelect Pty Ltd) Labelling Exemption 2022". Therapeutic Goods Administration (TGA). 21 June 2022. Archived from the original on 19 March 2023. Retrieved 9 April 2023.
  17. ^ "Nuvaxovid". Australian Public Assessment Report (AusPAR). The Department of Health and Aged Care, Australian Government.
  18. ^ Novavax, Inc. (24 March 2022). "Product Monograph, NUVAXOVID ™, COVID-19 Vaccine (Recombinant protein, Adjuvanted)" (PDF). Archived (PDF) from the original on 29 May 2022. Retrieved 14 July 2022.
  19. ^ "Novavax Nuvaxovid COVID-19 vaccine". Health Canada. 17 February 2022. Archived from the original on 29 May 2022. Retrieved 29 May 2022.
  20. ^ "Summary Basis of Decision (SBD) for Nuvaxovid". Health Canada. 23 October 2014. Archived from the original on 29 May 2022. Retrieved 29 May 2022.
  21. ^ "Nuvaxovid". Health Canada. 17 February 2022. Archived from the original on 1 June 2022. Retrieved 31 May 2022.
  22. ^ "Summary Basis of Decision (SBD) for Nuvaxovid XBB.1.5". Health Canada. 9 February 2024. Retrieved 24 February 2024.
  23. ^ "Novavax COVID-19 Vaccine: Standing Orders for Administering Vaccine to Persons 12 Years of Age and Older" (PDF). Centers for Disease Control and Prevention. 22 August 2022. Archived (PDF) from the original on 3 August 2022. Retrieved 3 September 2022.
  24. ^ "Coronavirus (COVID-19) Update: FDA Authorizes Emergency Use of Novavax COVID-19 Vaccine, Adjuvanted" (Press release). U.S. Food and Drug Administration. 13 July 2022. Archived from the original on 15 July 2022. Retrieved 15 July 2022.
  25. ^ "Novavax COVID-19 Vaccine". U.S. Food and Drug Administration. 13 July 2022. Archived from the original on 14 July 2022. Retrieved 15 July 2022.
  26. ^ Novavax, Inc. (13 July 2022). "Novavax HCP Fact Sheet 07132022". Food and Drug Administration. Archived from the original on 14 July 2022. Retrieved 15 July 2022.
  27. ^ "FDA Roundup: August 19, 2022". U.S. Food and Drug Administration (Press release). 19 August 2022. Archived from the original on 21 August 2022. Retrieved 20 August 2022.
  28. ^ "Novavax COVID-19 Vaccine, Adjuvanted- nvx-cov2373 injection, suspension". DailyMed. 11 October 2023. Retrieved 18 December 2023.
  29. ^ Cite error: The named reference FDA Novavax COVID-19 Vaccine, Adjuvanted was invoked but never defined (see the help page).
  30. ^ a b "Novavax COVID-19 Vaccine, Adjuvanted- nvx-cov2705 injection, suspension". DailyMed. 3 September 2024. Retrieved 16 September 2024.
  31. ^ "COVID-19 medicines". European Medicines Agency (EMA). 14 October 2024. Retrieved 14 October 2024.
  32. ^ Leo L (27 March 2021). "Hope to launch Covovax by September, says Serum Institute CEO". mint. Archived from the original on 13 May 2021. Retrieved 28 March 2021.
  33. ^ "FDA Authorizes Updated Novavax COVID-19 Vaccine Formulated to Better Protect Against Currently Circulating Variants". U.S. Food and Drug Administration (FDA) (Press release). 3 October 2023. Archived from the original on 4 October 2023. Retrieved 4 October 2023. Public Domain This article incorporates text from this source, which is in the public domain.

Rich TVX News Network Site

Rich TVX News Network Info

© MMXXIII Rich X Search. We shall prevail. All rights reserved. Rich X Search